Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 11/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2207310 | 0.82 | APP (0.46) | — | |
| SCHEMBL4528939 | 0.81 | ABCG2 (0.40) | ABCG2GRM4 | |
| SCHEMBL3547401 | 0.78 | PDE5A (0.46) | — | |
| SCHEMBL1164979 | 0.76 | PAK4 (0.46) | — | |
| SCHEMBL3340680 | 0.75 | NTRK1 (0.42) | CYP1A2 | |
| SCHEMBL3339748 | 0.75 | NTRK1 (0.43) | — | |
| SCHEMBL4068340 | 0.75 | — | — | |
| SCHEMBL3767642 | 0.74 | PAK4 (0.36) | — | |
| SCHEMBL3852710 | 0.74 | IGF1R (0.41) | — | |
| SCHEMBL30227668 | 0.72 | PLK4 (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152219-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA R&D (SE) | 2010-06-17 | — | — | US | disclosed |
| EP-1686999-B1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2009-07-01 | — | — | EP | disclosed |
| US-20070142413-A1 | Pyrazole derivatives as inhibitors of receptor tyrosone kinases | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| CN-1905884-A | Pyrazole derivatives as inhibitors of receptor tyrosyne kinases | ASTRAZENECA AB (SE) | 2007-01-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152219-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | LTK, ERBB2, ERBB3 | ABCG2 1310/4885GRM4 1517/4885CYP1A2 1559/4885 |
| US-20070142413-A1 | Pyrazole derivatives as inhibitors of receptor tyrosone kinases | PRKDC, MUSK, LTK | ABCG2 1660/4885GRM4 1899/4885CYP1A2 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.